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HOming in on arteriovenous 
fistula survival
W Durante1,6 and C-C Lin2,3,4,5,6
Vascular access failure is a major clinical problem for patients on 
hemodialysis, but therapeutic approaches aimed at improving 
arteriovenous fistula (AVF) dysfunction remain elusive. Using a murine 
AVF model, Juncos et al. demonstrate for the first time that the stress 
protein heme oxygenase-1 (HO-1) is induced in AVFs and that HO-1 is a 
critical determinant of AVF survival.
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Hemodialysis vascular access failure 
is the dominant cause of morbidity in 
patients with end-stage renal disease 
and contributes substantially to the 
economic burden of this patient popu-
lation. Vascular access complications 
account for about 20% of the hospitali-
zation of hemodialysis patients in the 
United States, with an annual cost of $1 
billion.1 The native arteriovenous ﬁstula 
(AVF) is the preferred form of dialysis 
access but suﬀers from frequent failure. 
According to an analysis of the pooled 
data by the Dialysis Outcomes Quality 
Initiative committee, the primary pat-
ency of AVFs was 85% at 1 year and 75% 
at 2 years after exclusion of patients with 
primary failure, the rate of which may 
be up to 50% in some centers. The major 
cause of AVF dysfunction is neointimal 
hyperplasia leading to the develop-
ment of venous stenosis and subsequent 
thrombosis. Significantly, neointimal 
hyperplasia has also been implicated in 
the failure of AVFs to mature and accom-
modate the increased rate of blood ﬂow 
required for eﬀective dialysis. Histologi-
cally, these neointimal lesions consist 
of proliferating and migrating vascular 
smooth muscle cells (VSMCs), infil-
trating inﬂammatory cells, substantial 
amounts of extracellular matrix, and 
angiogenesis in both the adventitia and 
the intima of the lesion.2 Multiple fac-
tors are believed to contribute to the 
pathogenesis of neointimal hyperplasia 
following the creation of AVFs, includ-
ing surgical injury, hemodynamic stress, 
platelet activation, endothelial dysfunc-
tion, oxidative stress, inﬂammation, and 
uremia. Although ever more sophisti-
cated surveillance techniques can reliably 
detect subcritical and critical stenoses, 
therapeutic interventions that target this 
lesion and substantially prolong patency 
remain elusive.
Heme oxygenase-1 (HO-1) is a highly 
inducible stress protein that mediates 
important vasoprotective actions in the 
circulation.3 Pharmacological induc-
tion of HO-1 or adenovirus-mediated 
HO-1 gene delivery attenuates neointi-
mal hyperplasia in injured arteries and 
retards the development of athero-
sclerotic plaques in murine models of 
atherosclerosis, whereas inhibition of 
HO-1 activity enhances lesion formation. 
In addition, HO-1-deﬁcient mice display 
enhanced neointimal thickening follow-
ing wire-induced arterial injury, robust 
VSMC proliferation in a murine vein 
graft model, and accelerated lesion for-
mation in an atherogenic rodent model. 
Moreover, HO-1 may also regulate the 
vascular response to injury in humans, 
since a long guanine–thymidine (GT) 
dinucleotide repeat microsatellite poly-
morphism in the human HO-1 promoter 
that is linked with impaired inducibility 
is associated with susceptibility to rest-
enosis in patients undergoing percutane-
ous transluminal angioplasty or coronary 
artery stenting. Interestingly, we recently 
demonstrated that the same length poly-
morphism in the HO-1 promoter is asso-
ciated with stenosis-related AVF failure 
in Chinese hemodialysis patients.4 In 
particular, we found that long GT repeats 
((GT)n ≥ 30) in the HO-1 promoter are 
associated with a higher frequency of 
access failure and poorer patency of 
AVFs. On the basis of these ﬁndings, we 
speculated that longer GT repeats in the 
HO-1 promoter might limit gene tran-
scription and consequently offset the 
protective eﬀect of HO-1 against vascu-
lar injury.
Juncos and colleagues5 (this issue) 
now directly demonstrate for the ﬁrst 
time that HO-1 plays a critical role in 
promoting AVF survival. The authors 
took advantage of a recently developed 
murine AVF model6 that recapitulates 
the salient features of dysfunctional 
AVFs in humans, including neointima 
formation and thrombosis, to show 
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that HO-1 gene deletion exacerbates 
neointimal hyperplasia and AVF failure. 
In this model, an AVF is constructed by 
an end-to-end anastomosis between the 
mouse right common carotid artery and 
jugular vein. Robust induction of both 
HO-1 mRNA and protein is observed 
within 1 week in the venous wall of the 
ﬁstula, predominantly by cells with phe-
notypic characteristics of VSMCs. Nota-
bly, AVFs remain fully patent for up to 
3 weeks in all wild-type animals. In con-
trast, induction of HO-1 is not observed 
in the fistulas of homozygous HO-1-
deficient mice, and the AVF patency 
rate declines by one-third in these ani-
mals. In addition, the impaired patency 
rate in HO-1-null animals is associated 
with more exuberant venous neointimal 
hyperplasia, as reﬂected by increases in 
venous wall thickening and decreases in 
luminal area/venous wall cross-section 
in HO-1-deﬁcient mice compared with 
wild-type animals. Finally, the authors 
also examined the eﬀect of HO-1 gene 
deletion on the expression of genes 
that may contribute to AVF failure and 
found that the expression of plasmino-
gen activator inhibitor-1, monocyte 
chemoattractant protein-1, and matrix 
metalloproteinase-2 and -9 is markedly 
elevated in AVFs of HO-1-deﬁcient mice 
compared with wild-type animals.
These findings by Juncos et al.5 are 
highly signiﬁcant and set the stage for 
further studies exploring the role of 
HO-1 in AVF survival. The ability of 
HO-1 to suppress monocyte chemo-
attractant protein-1 expression suggests 
that recruitment of inﬂammatory cells 
into the neointima may be enhanced in 
HO-1-deﬁcient animals. Furthermore, 
the striking increase in plasminogen acti-
vator inhibitor-1 expression in the ﬁstu-
las of HO-1-null mice may contribute to 
a procoagulant state in these animals. A 
comprehensive examination of the extent 
of leukocyte inﬁltration, ﬁbrin forma-
tion, and platelet thrombosis in AVFs 
from both wild-type and HO-1-null mice 
would conﬁrm whether HO-1 is exerting 
anti-inﬂammatory and antithrombotic 
eﬀects in this setting. In addition, stud-
ies exploring how HO-1 is regulating 
cellular hyperplasia within the lesion 
would provide important mechanistic 
information. Is HO-1 inﬂuencing the rate 
of VSMC growth or apoptosis, or both? 
Alternatively, the capacity of HO-1 to 
inhibit gelatinase activity may also serve 
to reduce the number of VSMCs in the 
lesion by restricting their migration from 
the media to the intima. The synthesis 
of extracellular matrix components is 
another critical determinant of lesion 
size and may provide an additional path-
way by which HO-1 regulates neointimal 
thickening. Although loss of HO-1 clearly 
promotes AVF failure, it will be impor-
tant to extend this study beyond 3 weeks 
and determine whether overexpression 
of HO-1 will prolong the lifespan of 
AVFs in wild-type animals. Furthermore, 
elucidation of the kinetics as well as the 
stimulus for HO-1 induction in AVFs 
would be of interest. Determination of 
the reaction product or products that 
mediate the protective action of HO-1 
would also represent a logical extension 
of the study by Juncos et al.5 Finally, it 
will be essential to validate the beneﬁ-
cial actions of HO-1 on AVF stenosis and 
dysfunction in larger animals that utilize 
more relevant peripheral vessels.
A model demonstrating the protec-
tive role of HO-1 in AVFs is shown in 
Figure 1. Although the mechanism 
responsible for the induction of HO-1 in 
AVFs is not known, surgical injury and 
increases in oxidative and inﬂammatory 
stress that occur following the placement 
of a fistula are likely to contribute. In 
addition, changes in hemodynamics fol-
lowing the creation of AVFs may be par-
ticularly relevant, as increases in venous 
ﬂow will elevate ﬂuid shear stress and cir-
cumferential wall strain, which are estab-
lished inducers of HO-1.7 The induction 
of HO-1 serves an important adaptive 
protective response in AVFs by generat-
ing a cascade of reaction products. HO-
1 catalyzes the oxidative degradation of 
heme into equimolar amounts of carbon 
monoxide (CO), free iron, and biliverdin. 
Biliverdin is subsequently metabolized 
to bilirubin by biliverdin reductase, and 
iron leads to the induction of ferritin. 
These HO-1 products are known to exert 
Figure 1 | Model for the protective role of heme oxygenase-1 in arteriovenous fistula failure. 
Several factors (surgical injury, oxidative stress, inflammatory stress, and hemodynamic stress) 
associated with the creation of an AVF lead to the induction of HO-1 in the fistula. HO-1 mediates 
the oxidative metabolism of heme to carbon monoxide (CO), iron (Fe), and biliverdin. Subsequently, 
biliverdin is converted to bilirubin, and iron stimulates ferritin expression. These HO-1 products 
possess potent antiproliferative, antithrombotic, anti-inflammatory, antifibrotic, antioxidant, and 
vasodilatory effects that limit AVF stenosis. SMC, smooth muscle cell; EC, endothelial cell.
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potent antiproliferative, antithrombotic, 
anti-inﬂammatory, antiﬁbrotic, antioxi-
dant, and vasodilatory actions that will 
mitigate AVF stenosis.3 Significantly, 
the local administration of biliverdin/
bilirubin or CO protects against neointi-
mal hyperplasia in other models of vas-
cular injury.3,8
The study of Juncos and colleagues5 
provides a strong rationale for the devel-
opment of therapeutic interventions that 
target HO-1 in AVF failure. Given their 
superﬁcial position, the local application 
of pharmacological inducers of HO-1 to 
AVFs offers one promising approach. 
A large number of chemically diverse 
inducers of HO-1 have been identiﬁed, 
and many of them are capable of inhib-
iting neointima formation in animal 
models of balloon angioplasty. Interest-
ingly, some of the therapeutic approaches 
being developed to treat AVF failure may 
mediate their beneﬁcial eﬀect through 
the induction of HO-1. We recently 
demonstrated that local application of 
far infrared radiation improves blood 
flow and patency of AVFs as well as 
systemic inﬂammation in hemodialysis 
patients, and we subsequently found that 
HO-1 mediates the anti-inﬂammatory 
eﬀect of far infrared therapy.9,10 Simi-
larly, rapamycin and paclitaxel, which 
have been shown to suppress luminal 
stenosis in diﬀerent animal models of 
AVF failure, exert their antiproliferative 
effect on VSMCs via the induction of 
HO-1.3 Although these studies attest to 
the therapeutic potential of using HO-1 
inducers, the GT length polymorphism 
in the HO-1 promoter may limit the 
utility of this approach in some patients. 
Increasing HO-1 expression via virus-
mediated delivery of HO-1 circumvents 
this problem and may provide a more 
speciﬁc approach in raising HO-1 protein 
levels. Alternatively, the local delivery of 
HO-1 products aﬀords another potential 
therapeutic avenue for the treatment of 
AVF failure.
In conclusion, the study by Juncos 
and colleagues5 is HOming in on AVF 
survival and has identiﬁed HO-1 as a 
critical determinant of AVF function. 
Treatment modalities that locally target 
HO-1 or its reaction products to AVFs 
represent a promising new approach 
in overcoming the recalcitrant clinical 
problem of AVF stenosis.
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